Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer
Nagaraj S. Nagathihalli, Jason Castellanos, Purushottam Lamichhane, et al.
Cancer Research (2018) Vol. 78, Iss. 21, pp. 6235-6246
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer
Jashodeep Datta, Xizi Dai, Anna Bianchi, et al.
Gastroenterology (2022) Vol. 163, Iss. 6, pp. 1593-1612
Open Access | Times Cited: 105
Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Anna Bianchi, Iago De Castro Silva, Nilesh Deshpande, et al.
Cancer Discovery (2023) Vol. 13, Iss. 6, pp. 1428-1453
Open Access | Times Cited: 67
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Pingping Hou, Avnish Kapoor, Qiang Zhang, et al.
Cancer Discovery (2020) Vol. 10, Iss. 7, pp. 1058-1077
Open Access | Times Cited: 123
Novel activators and small-molecule inhibitors of STAT3 in cancer
Lehe Yang, Shichong Lin, Lingyuan Xu, et al.
Cytokine & Growth Factor Reviews (2019) Vol. 49, pp. 10-22
Open Access | Times Cited: 111
Markers of pancreatic cancer stem cells and their clinical and therapeutic implications
Arkadiusz Gzil, Izabela Zarębska, Wiktor Bursiewicz, et al.
Molecular Biology Reports (2019) Vol. 46, Iss. 6, pp. 6629-6645
Open Access | Times Cited: 96
Modeling pancreatic cancer in mice for experimental therapeutics
Kavita Mallya, Shailendra K. Gautam, Abhijit Aithal, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 1, pp. 188554-188554
Open Access | Times Cited: 57
Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance
Shengwei Jiang, Tingwei Deng, Huan Cheng, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 29
Tumor Cell–Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer
Samara P. Singh, Austin R. Dosch, Siddharth Mehra, et al.
Cancer Research (2024) Vol. 84, Iss. 8, pp. 1320-1332
Open Access | Times Cited: 15
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 12
Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
Shihui Bao, Hailun Zheng, Jinyao Ye, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 41
Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer
Austin R. Dosch, Samara P. Singh, Xizi Dai, et al.
Molecular Cancer Therapeutics (2021) Vol. 20, Iss. 11, pp. 2280-2290
Open Access | Times Cited: 41
Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis
Howard C. Crawford, Marina Pasca di Magliano, Sulagna Banerjee
Gastroenterology (2019) Vol. 156, Iss. 7, pp. 2073-2084
Open Access | Times Cited: 53
Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome
Luisa Benerini Gatta, Laura Melocchi, Mattia Bugatti, et al.
Cancers (2019) Vol. 11, Iss. 9, pp. 1219-1219
Open Access | Times Cited: 44
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer
Austin R. Dosch, Xizi Dai, Michelle L. Reyzer, et al.
Molecular Cancer Research (2020) Vol. 18, Iss. 4, pp. 623-631
Open Access | Times Cited: 43
The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells
Luisa Klemke, Clara F. Fehlau, Nadine Winkler, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 37
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Martin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Trends in cancer (2022) Vol. 9, Iss. 1, pp. 42-54
Open Access | Times Cited: 28
High expression of STAT3 within the tumour‐associated stroma predicts poor outcome in breast cancer patients
Elizabeth Morrow, Kathryn A.F. Pennel, Phimmada Hatthakarnkul, et al.
Cancer Medicine (2023) Vol. 12, Iss. 12, pp. 13225-13240
Open Access | Times Cited: 14
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Rodrigo Entrialgo‐Cadierno, Cristina Cueto‐Ureña, Connor Welch, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma
Lakshana Sreenivasan, Hui Wang, Shyong Quin Yap, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 12
Open Access | Times Cited: 37
Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation
Weikun Qian, Qigui Xiao, Lin Wang, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 127, pp. 110116-110116
Open Access | Times Cited: 34
Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
Zhen-Yuan Zheng, Man-Yu Chu, Wan‐Wan Lin, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 5
Open Access | Times Cited: 21
The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment
Mengxuan Zhu, Suyao Li, Xin Cao, et al.
Seminars in Cancer Biology (2022) Vol. 88, pp. 18-31
Closed Access | Times Cited: 21
STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage
Hangcheng Guo, Zujian Hu, Xuejia Yang, et al.
International Immunopharmacology (2023) Vol. 123, pp. 110709-110709
Closed Access | Times Cited: 11
New insights into Notch signaling as a crucial pathway of pancreatic cancer stem cell behavior by chrysin-polylactic acid-based nanocomposite
Eman M. Ragab, Doaa M. El Gamal, Fares F. Elnajjar, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
Page 1 - Next Page

Scroll to top